# Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

> **NCT06465732** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 220 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT06465732
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2025-11
- **Final completion:** 2026-07
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465732, "Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06465732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*